{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:12:25Z","timestamp":1792959145567,"version":"4.5.0"},"reference-count":257,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009965","name":"Dalian Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009965","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.mam.2024.101335","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T23:52:08Z","timestamp":1735689128000},"page":"101335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy"],"prefix":"10.1016","volume":"101","author":[{"given":"Deqian","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guandu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunwen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2300-8465","authenticated-orcid":false,"given":"Guangzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mam.2024.101335_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12032-024-02484-5","article-title":"Lipid metabolism reprogramming in renal cell carcinomas","volume":"41","author":"Abduljabbar","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11864-023-01106-y","article-title":"Targeting HIF-2 alpha in renal cell carcinoma","volume":"24","author":"Ahmed","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13238-018-0586-8","article-title":"Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch","volume":"10","author":"Aki","year":"2018","journal-title":"Prot. Cell"},{"key":"10.1016\/j.mam.2024.101335_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115787","article-title":"The Warburg effect explained: integration of enhanced glycolysis with heterogeneous mitochondria to promote cancer cell proliferation","volume":"24","author":"Alberghina","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/oncolo\/oyac262","article-title":"Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas","volume":"28","author":"Alhalabi","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.mam.2024.101335_bib6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib8","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.21873\/anticanres.16675","article-title":"Renal cell cancer \u2013 insights in drug resistance mechanisms","volume":"43","author":"Aweys","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib9","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.3390\/ijms24098391","article-title":"PI3K\/AKT\/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL\/HIF Axis","volume":"24","author":"Badoiu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-020-00181-3","article-title":"The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017","volume":"9","author":"Bai","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007124","article-title":"Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling","volume":"4","author":"Balgi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2024.101335_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12860-021-00370-w","article-title":"Complex II subunit SDHD is critical for cell growth and metabolism, which can be partially restored with a synthetic ubiquinone analog","volume":"22","author":"Bandara","year":"2021","journal-title":"BMC Mol. Cell Biol."},{"key":"10.1016\/j.mam.2024.101335_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43046-023-00186-z","article-title":"Mechanisms of HIF-driven immunosuppression in tumour microenvironment","volume":"35","author":"Bandopadhyay","year":"2023","journal-title":"J. Egypt. Nat. Cancer Inst."},{"key":"10.1016\/j.mam.2024.101335_bib14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00345-012-0874-5","article-title":"Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1\/PARK7 in renal cell carcinoma (RCC)","volume":"31","author":"Baumunk","year":"2013","journal-title":"World J. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib15","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37868","article-title":"Loss of p53 suppresses replication-stress-induced DNA breakage in G1\/S checkpoint deficient cells","volume":"7","author":"Benedict","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.mam.2024.101335_bib16","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/bloodadvances.2019001393","article-title":"AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma","volume":"4","author":"Bloedjes","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.mam.2024.101335_bib17","series-title":"The Heterogeneity of Cancer Metabolism","first-page":"3","article-title":"Glucose metabolism in cancer: the Warburg effect and beyond","author":"Bose","year":"2021"},{"key":"10.1016\/j.mam.2024.101335_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814356","article-title":"Exosomes in the diagnosis and treatment of renal cell cancer","volume":"24","author":"Boussios","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00428-022-03380-x","article-title":"TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms","volume":"481","author":"Cali\u00f2","year":"2022","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mam.2024.101335_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12672-022-00579-x","article-title":"BAP1 in cancer: epigenetic stability and genome integrity","volume":"13","author":"Caporali","year":"2022","journal-title":"Discov. Onc."},{"key":"10.1016\/j.mam.2024.101335_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13046-021-01887-w","article-title":"ROS-dependent HIF1\u03b1 activation under forced lipid catabolism entails glycolysis and mitophagy as mediators of higher proliferation rate in cervical cancer cells","volume":"40","author":"Castelli","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib24","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","article-title":"PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer","volume":"81","author":"Chabanon","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.euf.2021.04.014","article-title":"Correlating immune cell infiltration patterns with recurrent somatic mutations in advanced clear cell renal cell carcinoma","volume":"8","author":"Chakiryan","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.mam.2024.101335_bib26","first-page":"1","article-title":"The cancer driver genes IDH1\/2, JARID1C\/KDM5C, and UTX\/KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism","volume":"51","author":"Chang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.mam.2024.101335_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s13402-024-00978-y","article-title":"Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity","author":"Chang","year":"2024","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1541-7786.MCR-06-0353","article-title":"MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins","volume":"5","author":"Chaturvedi","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/cancers15030565","article-title":"An update on the treatment of papillary renal cell carcinoma","volume":"15","author":"Chawla","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2024.101335_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clgc.2022.11.007","article-title":"Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors","volume":"21","author":"Chawla","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib31","first-page":"1","article-title":"Regulating tumor suppressor genes: post-translational modifications","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mam.2024.101335_bib32","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.7150\/jca.50293","article-title":"BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma","volume":"12","author":"Chen","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12967-022-03858-x","article-title":"Cell\u2013cell communications shape tumor microenvironment and predict clinical outcomes in clear cell renal carcinoma","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mam.2024.101335_bib34","article-title":"MUC1 and MUC16: critical for immune modulation in cancer therapeutics","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mam.2024.101335_bib35","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3390\/ijms24065821","article-title":"Molecular anatomy of the EML4-ALK fusion protein for the development of novel anticancer drugs","volume":"24","author":"Cheon","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.18632\/aging.100974","article-title":"mTORC1 regulates nutrient access in Ras-mediated tumors","volume":"8","author":"Cheong","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.mam.2024.101335_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12951-023-02122-8","article-title":"Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles","volume":"21","author":"Chong","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mam.2024.101335_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic lethal targeting of cyclin dependent kinase-12-deficient prostate cancer with PARP inhibitors","author":"Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2024.101335_bib40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfae036","article-title":"Global epidemiology of kidney cancer","volume":"39","author":"Cirillo","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.mam.2024.101335_bib41","unstructured":"Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Cancer Research UK Cambridge Institute https:\/\/www.cruk.cam.ac.uk\/publications\/clinical-and-pathological-impact-of-vhl-pbrm1-bap1-setd2-kdm6a-and-jarid1c-in-clear-cell-renal-cell-carcinoma\/[Accessed October 18, 2024]."},{"key":"10.1016\/j.mam.2024.101335_bib42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.eururo.2023.04.003","article-title":"Current landscape of genomic biomarkers in clear cell renal cell carcinoma","volume":"84","author":"Cotta","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib43","series-title":"Epigenetics - Regulation and New Perspectives","article-title":"Chromatin dynamics: chromatin remodeler, epigenetic modification and diseases","author":"Cui","year":"2022"},{"key":"10.1016\/j.mam.2024.101335_bib44","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1007\/s12094-024-03478-5","article-title":"The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review","volume":"26","author":"Da","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semcancer.2019.12.007","article-title":"The CXCL12-CXCR4\/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies","volume":"65","author":"Daniel","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.mam.2024.101335_bib46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12935-023-03019-0","article-title":"Glycolysis-related biomarker TCIRG1 participates in regulation of renal cell carcinoma progression and tumor immune microenvironment by affecting aerobic glycolysis and AKT\/mTOR signaling pathway","volume":"23","author":"Di","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib47","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbamcr.2011.05.001","article-title":"Bimodal regulation of FoxO3 by AKT and 14-3-3","volume":"1813","author":"Dobson","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mam.2024.101335_bib48","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3","volume":"34","author":"Dodd","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.mam.2024.101335_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s12967-023-04403-0","article-title":"Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis","volume":"21","author":"Duan","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mam.2024.101335_bib50","series-title":"Cdk12 Regulates DNA Repair Genes by Suppressing Intronic Polyadenylation","author":"Dubbury","year":"2018"},{"key":"10.1016\/j.mam.2024.101335_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.mam.2024.101335_bib52","series-title":"Cancer Metabolomics: Methods and Applications","first-page":"243","article-title":"HIF-1\u03b1 metabolic pathways in human cancer","author":"Elzakra","year":"2021"},{"issue":"2050","key":"10.1016\/j.mam.2024.101335_bib53","article-title":"Succinate dehydrogenase and human disease: novel insights into a well-known enzyme","volume":"12","author":"Esteban-Amo","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.mam.2024.101335_bib54","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib55","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1002\/cncr.33148","article-title":"Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: final results from a phase II trial","volume":"126","author":"Feldman","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00279","article-title":"Identifying BAP1 mutations in clear-cell renal cell carcinoma by CT radiomics: preliminary findings","volume":"10","author":"Feng","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib57","first-page":"1","article-title":"MDH2 regulates the sensitivity of clear cell renal cell carcinoma to ferroptosis through its interaction with FSP1","volume":"10","author":"Feng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mam.2024.101335_bib58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40336-018-0278-7","article-title":"PET\/CT for the diagnostic assessment of patients with renal cancer","volume":"6","author":"Fiasconaro","year":"2018","journal-title":"Clin. Transl. Imag."},{"key":"10.1016\/j.mam.2024.101335_bib59","article-title":"Low expression of mucin-4 predicts poor prognosis in patients with clear-cell renal cell carcinoma","volume":"95","author":"Fu","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.mam.2024.101335_bib60","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/ol.2021.13096","article-title":"Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway","volume":"22","author":"Gad","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mam.2024.101335_bib61","series-title":"Neuroscience in the 21st Century: from Basic to Clinical","first-page":"2677","article-title":"Epigenetic mechanisms: DNA methylation and histone protein modification","author":"Gagnidze","year":"2022"},{"key":"10.1016\/j.mam.2024.101335_bib62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00428-022-03451-z","article-title":"ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature","volume":"482","author":"Galea","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mam.2024.101335_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94132-5","article-title":"VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma","volume":"11","author":"Ganner","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2024.101335_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clgc.2018.04.001","article-title":"Comprehensive genomic profiling of metastatic tumors in a phase 2 biomarker study of everolimus in advanced renal cell carcinoma","volume":"16","author":"Gao","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12920-024-01957-w","article-title":"Case report: response to immunotherapy and association with the fh gene in hereditary leiomyomatosis and renal cell cancer-associated renal cell cancer","volume":"17","author":"Gao","year":"2024","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.mam.2024.101335_bib66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.eururo.2021.12.010","article-title":"Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis","volume":"81","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib67","series-title":"Clear Cell Renal Cell Carcinoma with Biallelic Inactivation of CDKN2A\/B on 9p21 Have Distinct Gene Expression Signature and Are Associated with Poor Prognosis","author":"Girgis","year":"2017"},{"key":"10.1016\/j.mam.2024.101335_bib68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1476-4598-13-101","article-title":"Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma","volume":"13","author":"Girgis","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib69","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib70","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase\u2013deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12951-024-02622-1","article-title":"Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy","volume":"22","author":"Gong","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mam.2024.101335_bib72","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.3390\/cimb46040203","article-title":"Radiogenomics and Texture Analysis to Detect von Hippel\u2013Lindau (VHL) Mutation in Clear Cell Renal Cell Carcinoma","volume":"46","author":"Greco","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.mam.2024.101335_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25288","article-title":"Adjuvant everolimus in non\u2013clear cell renal cell carcinoma: a secondary analysis of a randomized clinical trial","volume":"7","author":"Gulati","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.mam.2024.101335_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-018-0803-3","article-title":"PTEN\/PTENP1: \u2018Regulating the regulator of RTK-dependent PI3K\/Akt signalling\u2019, new targets for cancer therapy","volume":"17","author":"Haddadi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib75","series-title":"Tumor Microenvironment: Molecular Players \u2013 Part A","first-page":"113","article-title":"The immune consequences of lactate in the tumor microenvironment","author":"Harmon","year":"2020"},{"key":"10.1016\/j.mam.2024.101335_bib76","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib77","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/cncr.34757","article-title":"Targeted therapy for lung cancer: beyond EGFR and ALK","volume":"129","author":"Herrera-Ju\u00e1rez","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/KCA-180043","article-title":"The \u2018achilles heel\u2019 of metabolism in renal cell carcinoma: glutaminase inhibition as a rational treatment strategy","volume":"3","author":"Hoerner","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib79","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1476-4598-9-160","article-title":"Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-\u03b2 signaling","volume":"9","author":"Hong","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib80","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm.3930","article-title":"RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK\u2013positive lung cancer","volume":"21","author":"Hrustanovic","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.mam.2024.101335_bib81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib82","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10555-023-10129-8","article-title":"The strict regulation of HIF-1\u03b1 by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies","volume":"43","author":"Jawad","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.mam.2024.101335_bib84","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s43440-023-00504-1","article-title":"The Warburg effect: a score for many instruments in the concert of cancer and cancer niche cells","volume":"75","author":"Jaworska","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.mam.2024.101335_bib85","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.2217\/fon-2019-0363","article-title":"Analysis of TGCA data reveals genetic and epigenetic changes and biological function of MUC family genes in colorectal cancer","volume":"15","author":"Jiang","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib86","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1134\/S0006297918110019","article-title":"Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications","volume":"83","author":"Jiao","year":"2018","journal-title":"Biochem. Moscow"},{"key":"10.1016\/j.mam.2024.101335_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-022-01285-4","article-title":"Ribosome biogenesis in disease: new players and therapeutic targets","volume":"8","author":"Jiao","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mam.2024.101335_bib88","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib89","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.mam.2024.101335_bib90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13000-022-01238-z","article-title":"ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report","volume":"17","author":"Kai","year":"2022","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.mam.2024.101335_bib91","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287176","article-title":"Integration of pan-cancer multi-omics data for novel mixed subgroup identification using machine learning methods","volume":"18","author":"Khadirnaikar","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2024.101335_bib93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12882-024-03775-9","article-title":"Diagnosis of renal tumors in Birt-Hogg-Dube syndrome: clinical presentation and risk factors in a single-center retrospective cohort","volume":"25","author":"Kijlertsuphasri","year":"2024","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.mam.2024.101335_bib94","article-title":"The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: a retrospective study of tissue microarrays using immunohistochemistry","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2024.101335_bib95","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.eururo.2015.09.014","article-title":"Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase","volume":"69","author":"Kinnaird","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib96","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.euo.2023.10.017","article-title":"A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer","volume":"7","author":"Kotecha","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12929-022-00878-z","article-title":"Cancer-derived extracellular succinate: a driver of cancer metastasis","volume":"29","author":"Kuo","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib98","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s12185-020-02970-2","article-title":"Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dub\u00e9 syndrome","volume":"112","author":"Kurata","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.mam.2024.101335_bib99","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","article-title":"BAP1 as a guardian of genome stability: implications in human cancer","volume":"55","author":"Kwon","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.mam.2024.101335_bib100","series-title":"Renal Cell Carcinoma: Molecular Features and Treatment Updates","first-page":"253","article-title":"Tyrosine kinase inhibitors: sorafenib, sunitinib, axitinib, and pazopanib","author":"Kyriakopoulos","year":"2017"},{"key":"10.1016\/j.mam.2024.101335_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.609683","article-title":"MiT\/TFE family of transcription factors: an evolutionary perspective","volume":"8","author":"La Spina","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mam.2024.101335_bib102","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1464-410x.1998.00814.x","article-title":"p53 autoantibodies in patients with urological tumours","volume":"82","author":"Lang","year":"1998","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13046-023-02667-4","article-title":"High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma","volume":"42","author":"Lang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib104","first-page":"132","article-title":"Clinical development of metabolic inhibitors for oncology","author":"Lemberg","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mam.2024.101335_bib105","series-title":"The Heterogeneity of Cancer Metabolism","first-page":"13","article-title":"Glutamine metabolism in cancer","author":"Li","year":"2018"},{"key":"10.1016\/j.mam.2024.101335_bib106","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201949425","article-title":"TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8+ T-cell numbers","volume":"21","author":"Li","year":"2020","journal-title":"EMBO Rep."},{"key":"10.1016\/j.mam.2024.101335_bib107","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13046-020-01733-5","article-title":"Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation","volume":"39","author":"Li","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib108","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13046-021-02026-1","article-title":"Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1\u03b1, HIF2\u03b1, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma","volume":"40","author":"Li","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-022-00397-x","article-title":"Small biomarkers with massive impacts: PI3K\/AKT\/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma","volume":"10","author":"Li","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.mam.2024.101335_bib110","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1007\/s11033-023-08396-3","article-title":"Interaction between STK33 and autophagy promoted renal cell carcinoma metastasis by regulating mTOR\/ULK1 signaling pathway","volume":"50","author":"Li","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.mam.2024.101335_bib111","first-page":"13","article-title":"Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib112","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib113","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13072-024-00531-z","article-title":"Research progress of SWI\/SNF complex in breast cancer","volume":"17","author":"Li","year":"2024","journal-title":"Epigenet. Chromatin"},{"key":"10.1016\/j.mam.2024.101335_bib114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12964-023-01449-x","article-title":"Glutamine addiction in tumor cell: oncogene regulation and clinical treatment","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.mam.2024.101335_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011284","article-title":"Reciprocal dynamics of metabolism and mRNA translation in tumor angiogenesis","volume":"25","author":"Lidonnici","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib116","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","article-title":"A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma","volume":"29","author":"Ligon","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib117","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00432-014-1803-3","article-title":"Current clinical regulation of PI3K\/PTEN\/Akt\/mTOR signalling in treatment of human cancer","volume":"141","author":"Lim","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib118","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.2147\/CMAR.S249456","article-title":"Long non-coding RNA TTN-AS1 serves as a competing endogenous RNA of miR-195 to facilitate clear cell renal cell carcinoma progression","volume":"12","author":"Lin","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.mam.2024.101335_bib119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11033-023-08931-2","article-title":"The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers","volume":"51","author":"Lin","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.mam.2024.101335_bib120","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-18-1354","article-title":"The metabolic basis of kidney cancer","volume":"9","author":"Linehan","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mam.2024.101335_bib121","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1756-9966-30-76","article-title":"Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas","volume":"30","author":"Liu","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib122","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.CAN-20-2245","article-title":"Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib123","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics","volume":"4","author":"Liu","year":"2021","journal-title":"Prec. Clin. Med."},{"key":"10.1016\/j.mam.2024.101335_bib124","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","article-title":"Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications","volume":"17","author":"Liu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00365590151030705","article-title":"p53 expression in correlation to clinical outcome in patients with renal cell carcinoma","volume":"35","author":"Ljungberg","year":"2001","journal-title":"Scand. J. Urol. Nephrol."},{"key":"10.1016\/j.mam.2024.101335_bib126","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259114","article-title":"Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to mediate senescence onset after G2 arrest","volume":"135","author":"Lossaint","year":"2022","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.mam.2024.101335_bib127","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1186\/s12885-022-09935-0","article-title":"Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer","volume":"22","author":"Lu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: an emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.mam.2024.101335_bib129","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-022-02266-0","article-title":"Perfect match: mTOR inhibitors and tuberous sclerosis complex","volume":"17","author":"Luo","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mam.2024.101335_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2020.104466","article-title":"Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway","volume":"115","author":"Ma","year":"2020","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.mam.2024.101335_bib131","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3390\/ijms25063313","article-title":"A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update","volume":"25","author":"Magar","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib132","first-page":"12","article-title":"Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor\u2013resistant pancreatic ductal adenocarcinoma","author":"Malvi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib133","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1083\/jcb.200912024","article-title":"Metabolic control of G1\u2013S transition: cyclin E degradation by p53-induced activation of the ubiquitin\u2013proteasome system","volume":"188","author":"Mandal","year":"2010","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.mam.2024.101335_bib134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","article-title":"Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response","volume":"29","author":"Mandal","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib136","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-021-09959-1","article-title":"Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression","volume":"40","author":"Marimuthu","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.mam.2024.101335_bib137","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-023-01820-z","article-title":"Expression of mTOR in normal and pathological conditions","volume":"22","author":"Marques-Ramos","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib138","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/cancers15041316","article-title":"Downstream targets of VHL\/HIF-\u03b1 signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance","volume":"15","author":"Mazumder","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2024.101335_bib139","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10555-023-10155-6","article-title":"Metastasis suppressor genes and their role in the tumor microenvironment","volume":"42","author":"Megino-Luque","year":"2023","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.mam.2024.101335_bib140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00280-014-2668-5","article-title":"Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study","volume":"75","author":"Merchan","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.mam.2024.101335_bib141","article-title":"A novel variant in the gene in a Chinese family with Birt\u2013Hogg\u2013Dub\u00e9 syndrome","volume":"12","author":"Miao","year":"2024","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.mam.2024.101335_bib142","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib143","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00018-022-04352-9","article-title":"SETD2: from chromatin modifier to multipronged regulator of the genome and beyond","volume":"79","author":"Molenaar","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.mam.2024.101335_bib144","series-title":"MDH2 Is a Metabolic Switch Rewiring the Fuelling of Respiratory Chain and TCA Cycle","author":"Molini\u00e9","year":"2021"},{"key":"10.1016\/j.mam.2024.101335_bib145","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.3390\/cancers12113237","article-title":"Succinate dehydrogenase and ribonucleic acid networks in cancer and other diseases","volume":"12","author":"Moreno","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2024.101335_bib146","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2024.101335_bib147","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib148","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing Atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib149","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2023.0515","article-title":"Research progress in tumor angiogenesis and drug resistance in breast cancer","author":"Mou","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.mam.2024.101335_bib150","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3390\/ijms25042060","article-title":"Therapeutic targeting of hypoxia-inducible factors in cancer","volume":"25","author":"Musleh Ud Din","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib151","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10689-015-9837-5","article-title":"Birt\u2013Hogg\u2013Dub\u00e9 syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas","volume":"15","author":"N\u00e4f","year":"2016","journal-title":"Famil. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib152","first-page":"8","article-title":"Amino acid transporter SLC6A14 (ATB0,+) \u2013 a target in combined anti-cancer therapy","author":"Na\u0142\u0119cz","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mam.2024.101335_bib153","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"N\u00e9grier","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-019-0107-6","article-title":"Spontaneous mutations in the single TTN gene represent high tumor mutation burden","volume":"5","author":"Oh","year":"2020","journal-title":"npj Genom. Med."},{"key":"10.1016\/j.mam.2024.101335_bib155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13059-021-02384-1","article-title":"Roles of TET and TDG in DNA demethylation in proliferating and non-proliferating immune cells","volume":"22","author":"Onodera","year":"2021","journal-title":"Genome Biol."},{"key":"10.1016\/j.mam.2024.101335_bib156","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/cancers16132448","article-title":"Integrating omics data and AI for cancer diagnosis and prognosis","volume":"16","author":"Ozaki","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2024.101335_bib157","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mam.2024.101335_bib158","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1038\/onc.2011.174","article-title":"Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1\u03b1 mediated by the PTEN\/PI3K\/Akt pathway","volume":"30","author":"Park","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.mam.2024.101335_bib159","first-page":"13","article-title":"Functions and interactions of mammalian KDM5 demethylases","author":"Pavlenko","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.mam.2024.101335_bib160","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s11427-021-2048-2","article-title":"Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth","volume":"65","author":"Pei","year":"2022","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.mam.2024.101335_bib161","first-page":"12","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib162","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.mam.2024.101335_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14737159.2015.1068122","article-title":"BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies","volume":"15","author":"Piva","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.mam.2024.101335_bib164","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2021.01.003","article-title":"Efficacy and safety of Atezolizumab plus bevacizumab following disease progression on Atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: a randomized phase 2 clinical trial","volume":"79","author":"Powles","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib165","first-page":"356","article-title":"Glutaminase inhibition in renal cell carcinoma therapy","volume":"2","author":"Raczka","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.mam.2024.101335_bib166","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jim-2020-001524","article-title":"Role of AMPK\/mTOR-independent autophagy in clear cell renal cell carcinoma","volume":"68","author":"Radovanovic","year":"2020","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.mam.2024.101335_bib167","author":"Raghavan"},{"key":"10.1016\/j.mam.2024.101335_bib168","first-page":"9","article-title":"Folliculin: a regulator of transcription through AMPK and mTOR signaling pathways","author":"Ramirez Reyes","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mam.2024.101335_bib169","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.5858\/arpa.2017-0285-RS","article-title":"Succinate dehydrogenase complex: an updated review","volume":"142","author":"Rasheed","year":"2018","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.mam.2024.101335_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102882","article-title":"New rising entities in cancer of unknown primary: is there a real therapeutic benefit?","volume":"147","author":"Rassy","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.mam.2024.101335_bib171","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","article-title":"PIK3CA-mutations in breast cancer","volume":"196","author":"Reinhardt","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mam.2024.101335_bib172","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2024.101335_bib173","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/s41379-020-0607-z","article-title":"Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome","volume":"33","author":"Roldan-Romero","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.mam.2024.101335_bib174","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00428-020-02766-z","article-title":"ALK-rearranged renal cell carcinoma\u2014different morphological faces of a rare tumor","volume":"477","author":"Rupp","year":"2020","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mam.2024.101335_bib175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.591386","article-title":"CXCR4 and CXCR7 signaling pathways: a focus on the cross-talk between cancer cells and tumor microenvironment","volume":"11","author":"Santagata","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib176","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.3390\/cancers15123207","article-title":"Recent advances in the management of clear cell renal cell carcinoma: novel biomarkers and targeted therapies","volume":"15","author":"Schiavoni","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2024.101335_bib177","series-title":"Characterizing the Mechanism of Tumor Suppression by PBRM1 in Clear Cell Renal Cell Carcinoma","author":"Schoenfeld","year":"2015"},{"key":"10.1016\/j.mam.2024.101335_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108711","article-title":"In situ modeling of acquired resistance to RTK\/RAS-pathway-targeted therapies","volume":"27","author":"Sealover","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.mam.2024.101335_bib179","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood.2021011043","article-title":"Breakthrough science: hypoxia-inducible factors, oxygen sensing, and disorders of hematopoiesis","volume":"139","author":"Semenza","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.mam.2024.101335_bib180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10456-018-9600-2","article-title":"miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target","volume":"21","author":"Serocki","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.mam.2024.101335_bib181","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","article-title":"Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine","volume":"16","author":"Serrano","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mam.2024.101335_bib182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s44178-024-00071-2","article-title":"Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma","volume":"3","author":"Shen","year":"2024","journal-title":"Holist Integ. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib183","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine Axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mam.2024.101335_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100755","article-title":"New advances in cancer therapy targeting TGF-\u03b2 signaling pathways","volume":"31","author":"Shou","year":"2023","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.mam.2024.101335_bib185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/0008-5472.CAN-06-3114","article-title":"Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib186","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1541-7786.MCR-17-0320","article-title":"The MiTF\/TFE family of transcription factors: master regulators of organelle signaling, metabolism, and stress adaptation","volume":"15","author":"Slade","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib187","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.mam.2024.101335_bib188","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s40843-023-2774-8","article-title":"Inhibiting PI3K\/AKT\/mTOR signaling by metal-organic frameworks for overcoming multiple drug resistance in chemoradiotherapy","volume":"67","author":"Song","year":"2024","journal-title":"Sci. China Mater."},{"key":"10.1016\/j.mam.2024.101335_bib189","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/cells9071680","article-title":"Molecular protein and expression profile in the primary tumors of clear cell renal carcinoma and metastases","volume":"9","author":"Spirina","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.mam.2024.101335_bib190","article-title":"Current insights into the regulation of programmed cell death by TP53 mutation in cancer","volume":"12","author":"Su","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib191","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1002\/cncr.27391","article-title":"Identification of anaplastic lymphoma kinase fusions in renal cancer","volume":"118","author":"Sugawara","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib192","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","article-title":"Integrated molecular characterization of fumarate hydratase\u2013deficient renal cell carcinoma","volume":"27","author":"Sun","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib193","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12964-022-00859-7","article-title":"mTORC2: a multifaceted regulator of autophagy","volume":"21","author":"Sun","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.mam.2024.101335_bib194","series-title":"mTORC1\/S6K1 Signaling Promotes Sustained Oncogenic Translation through Modulating CRL3IBTK-Mediated Non-degradative Ubiquitination of eIF4A1","author":"Sun","year":"2023"},{"key":"10.1016\/j.mam.2024.101335_bib195","first-page":"13","article-title":"Genomic profiles of renal cell carcinoma in a small Chinese cohort","author":"Tai","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1184854","article-title":"Birt-Hogg-Dub\u00e9 syndrome with c.1579_1580insA variant in a Chinese family: a case report","volume":"10","author":"Tang","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.mam.2024.101335_bib197","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mam.2024.101335_bib198","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","article-title":"Prostate cancer and PARP inhibitors: progress and challenges","volume":"14","author":"Teyssonneau","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib199","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/2159-8290.CD-RW2021-062","article-title":"The HIF2\u03b1 inhibitor belzutifan shows signs of efficacy in kidney cancer","volume":"11","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mam.2024.101335_bib200","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/oncolo\/oyac158","article-title":"Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas","volume":"27","author":"Thouvenin","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.mam.2024.101335_bib201","first-page":"A68","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge","volume":"19","author":"Tomczak","year":"2015","journal-title":"Contemp. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib202","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbalip.2018.06.015","article-title":"Expression of AGPAT2, an enzyme involved in the glycerophospholipid\/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia","volume":"1863","author":"Triantafyllou","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.mam.2024.101335_bib203","first-page":"2957","article-title":"Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation","volume":"62","author":"Turner","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib204","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216077","article-title":"CRISPR\/Cas9 landscape: current state and future perspectives","volume":"24","author":"Tyumentseva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib205","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/1097-0142(20010801)92:3<519::AID-CNCR1350>3.0.CO;2-#","article-title":"Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma","volume":"92","author":"Vaishampayan","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib206","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41416-023-02412-w","article-title":"Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism","volume":"129","author":"Valcarcel-Jimenez","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib207","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00280-004-0969-9","article-title":"Southwest Oncology Group. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109","volume":"56","author":"Van Veldhuizen","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.mam.2024.101335_bib208","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/d41586-021-01943-7","article-title":"How the amino acid leucine activates the key cell-growth regulator mTOR","volume":"596","author":"Vellai","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.mam.2024.101335_bib209","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41585-022-00659-1","article-title":"PBRM1, SETD2 and BAP1 \u2014 the trinity of 3p in clear cell renal cell carcinoma","volume":"20","author":"Walton","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib210","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s43032-019-00091-8","article-title":"BRD7-Mediated miR-3148 inhibits progression of cervical cancer by targeting wnt3a\/\u03b2-catenin pathway","volume":"27","author":"Wang","year":"2020","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.mam.2024.101335_bib211","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000445125","article-title":"Inhibition of LDHA deliver potential anticancer performance in renal cell carcinoma","volume":"99","author":"Wang","year":"2017","journal-title":"Urol. Int."},{"key":"10.1016\/j.mam.2024.101335_bib212","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12943-018-0913-y","article-title":"Effects of tumor metabolic microenvironment on regulatory T cells","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib213","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41467-020-14601-9","article-title":"Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mam.2024.101335_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.mam.2024.101335_bib215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12935-023-02908-8","article-title":"Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer","volume":"23","author":"Wang","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib216","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2022.12.027","article-title":"Apatinib combined with camrelizumab in advanced acral melanoma patients: an open-label, single-arm phase 2 trial","volume":"182","author":"Wang","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mam.2024.101335_bib218","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/cancers16173069","article-title":"TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2024.101335_bib219","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40425-018-0452-5","article-title":"Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1","volume":"6","author":"Wen","year":"2018","journal-title":"J. Immunot. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib220","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41388-020-1234-3","article-title":"Modeling clear cell renal cell carcinoma and therapeutic implications","volume":"39","author":"Wolf","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.mam.2024.101335_bib221","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/0008-5472.CAN-20-3979","article-title":"mTOR activation initiates renal cell carcinoma development by coordinating ERK and p38MAPK","volume":"81","author":"Wu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2024.101335_bib222","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib223","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s40001-023-01449-0","article-title":"CENPE and LDHA were potential prognostic biomarkers of chromophobe renal cell carcinoma","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.mam.2024.101335_bib224","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1172\/JCI86120","article-title":"Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin","volume":"126","author":"Xu","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mam.2024.101335_bib225","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1172\/JCI129317","article-title":"Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy","volume":"129","author":"Xu","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mam.2024.101335_bib226","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00253-019-10257-8","article-title":"Targeting PI3K\/AKT\/mTOR-mediated autophagy for tumor therapy","volume":"104","author":"Xu","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.mam.2024.101335_bib227","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinomaFH","volume":"83","author":"Xu","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mam.2024.101335_bib228","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00262-024-03681-x","article-title":"Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma","volume":"73","author":"Xu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mam.2024.101335_bib229","first-page":"1","article-title":"A novel pathogenic variant of the FH gene in a family with hereditary leiomyomatosis and renal cell carcinoma","volume":"9","author":"Yagi","year":"2022","journal-title":"Hum. Genom. Var."},{"key":"10.1016\/j.mam.2024.101335_bib230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13148-011-0037-3","article-title":"Epigenetic regulation of mucin genes in human cancers","volume":"2","author":"Yamada","year":"2011","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.mam.2024.101335_bib231","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12964-018-0242-1","article-title":"Emerging roles and regulation of MiT\/TFE transcriptional factors","volume":"16","author":"Yang","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.mam.2024.101335_bib232","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s11010-022-04461-w","article-title":"Phosphoinositide 3-kinase\/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization","volume":"477","author":"Yang","year":"2022","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.mam.2024.101335_bib233","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1080\/21655979.2022.2062537","article-title":"Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis","volume":"13","author":"Yang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.mam.2024.101335_bib234","first-page":"1","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mam.2024.101335_bib235","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2: current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib236","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s12094-021-02645-2","article-title":"Targeting GLS1 to cancer therapy through glutamine metabolism","volume":"23","author":"Yu","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib237","first-page":"9","article-title":"Emerging roles of the tumor suppressor p53 in metabolism","author":"Yu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mam.2024.101335_bib238","first-page":"13","article-title":"Histone methyltransferase SETD2: an epigenetic driver in clear cell renal cell carcinoma","author":"Yu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib239","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mam.2024.101335_bib240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.21037\/atm.2019.08.113","article-title":"Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.mam.2024.101335_bib241","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12935-020-01670-5","article-title":"Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib242","article-title":"KDM5C represses FASN-mediated lipid metabolism to exert tumor suppressor activity in intrahepatic cholangiocarcinoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mam.2024.101335_bib243","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13201","article-title":"Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.mam.2024.101335_bib244","series-title":"Targeting Lysine Demethylases in Cancer and Other Human Diseases","first-page":"113","article-title":"KDM5 lysine demethylases in pathogenesis, from basic science discovery to the clinic","author":"Zhang","year":"2023"},{"key":"10.1016\/j.mam.2024.101335_bib245","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12967-024-05298-1","article-title":"Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mam.2024.101335_bib246","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00428-023-03700-9","article-title":"Genomic alterations and diagnosis of renal cancer","volume":"484","author":"Zhang","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mam.2024.101335_bib247","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41467-023-44239-2","article-title":"Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mam.2024.101335_bib248","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12894-024-01559-9","article-title":"Frequent gene mutations and the correlations with clinicopathological features in clear cell renal cell carcinoma: preliminary study based on Chinese population and TCGA database","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Urol."},{"key":"10.1016\/j.mam.2024.101335_bib249","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-024-02044-5","article-title":"Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma","volume":"23","author":"Zhao","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007678","article-title":"Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway","volume":"11","author":"Zheng","year":"2023","journal-title":"J. Immunot. Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib251","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1186\/s12885-023-10920-4","article-title":"SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy","volume":"23","author":"Zheng","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mam.2024.101335_bib252","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12935-019-0898-7","article-title":"YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway","volume":"19","author":"Zhou","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mam.2024.101335_bib253","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2020.11.049","article-title":"Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer","volume":"500","author":"Zhou","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mam.2024.101335_bib254","first-page":"14","article-title":"Metabolic reprogramming of clear cell renal cell carcinoma","author":"Zhu","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mam.2024.101335_bib255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11033-023-09097-7","article-title":"TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress","volume":"51","author":"Zhu","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.mam.2024.101335_bib256","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12894-024-01580-y","article-title":"Advancements in research on lactate dehydrogenase A in urinary system tumors","volume":"24","author":"Zhuo","year":"2024","journal-title":"BMC Urol."},{"key":"10.1016\/j.mam.2024.101335_bib257","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299724000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299724000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T09:48:56Z","timestamp":1737280136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299724000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":257,"alternative-id":["S0098299724000943"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2024.101335","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2024.101335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101335"}}